GeoVax Q2 Loss Narrows to $4.4M, Cash Holds at $3.1M; Pivotal GEO-MVA Study Set for Q4
GOVX is trading near its 52-week low of $0.689 (10% above the low).
Summary
GeoVax's Q2 loss narrowed to $4.4M as it cut R&D costs, but cash stayed flat at $3.1M. The company is betting on a pivotal GEO-MVA study in Q4 under an expedited EMA pathway, while discontinuing its COVID-19 vaccine program.
Key Events · Earnings and Guidance · GOVX
-
Q2 Net Loss Narrows to $4.4M
Net loss of $4.4M ($0.97/share) vs $5.4M ($8.74/share) in Q2 2025, driven by lower R&D expenses after BARDA contract termination.
-
Cash Unchanged at $3.1M
Cash and equivalents held at $3.1M as of June 30, 2026, unchanged from December 31, 2025, indicating limited runway.
-
Strategic Pivot Away from COVID-19 Vaccine
Discontinued GEO-CM04S1 program to focus resources on GEO-MVA (mpox/smallpox) and Gedeptin (immuno-oncology), citing contraction of COVID-19 vaccine market.
-
Pivotal GEO-MVA Study Planned for Q4 2026
Initiation of pivotal immunobridging study under expedited EMA pathway expected in Q4 2026, with clinical trial material already manufactured.
Analysis · GOVX · Life Sciences
A narrower Q2 net loss of $4.4 million, down from $5.4 million a year ago, reflects reduced R&D spending after the BARDA contract termination. Cash remained at $3.1 million, unchanged from year-end, but the company faces a critical liquidity crunch with only months of runway. The strategic pivot away from COVID-19 vaccine GEO-CM04S1 toward GEO-MVA and Gedeptin sharpens focus on nearer-term regulatory milestones, including a planned Q4 pivotal immunobridging study under an expedited EMA pathway. However, the unchanged cash position and recent Nasdaq delisting notice for equity shortfall underscore the urgent need for additional financing to fund operations and the upcoming trial.
At the time of this filing, GOVX was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.69 to $20.64. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.